{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:33:54Z","timestamp":1772148834926,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.transproceed.2005.07.032","type":"journal-article","created":{"date-parts":[[2005,10,18]],"date-time":"2005-10-18T20:49:00Z","timestamp":1129668540000},"page":"3182-3186","source":"Crossref","is-referenced-by-count":48,"title":["Does Valganciclovir Hydrochloride (Valcyte) Provide Effective Prophylaxis Against Cytomegalovirus Infection in Liver Transplant Recipients?"],"prefix":"10.1016","volume":"37","author":[{"given":"A.","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Lansing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mohanka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Menegus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bozorgzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2005.07.032_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0168-8278(96)80083-3","article-title":"CMV infection of transplant recipients","volume":"25","author":"Mutimer","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.transproceed.2005.07.032_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0889-8553(21)00072-8","article-title":"Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation","volume":"22","author":"Wiesner","year":"1993","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.transproceed.2005.07.032_bib3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1086\/339449","article-title":"Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients","volume":"185","author":"Paya","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transproceed.2005.07.032_bib4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003495-200161080-00016","article-title":"Ganciclovir","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.transproceed.2005.07.032_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-199856010-00012","article-title":"Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients","volume":"56","author":"Noble","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.transproceed.2005.07.032_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-199707150-00013","article-title":"Prophylaxis of cytomegalovirus infection in liver transplantation","volume":"64","author":"Badley","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2005.07.032_bib7","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2005.07.032_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.7326\/0003-4819-120-5-199403010-00004","article-title":"High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial","volume":"120","author":"Singh","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transproceed.2005.07.032_bib9","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1097\/00007890-199812270-00036","article-title":"Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy","volume":"66","author":"Turgeon","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2005.07.032_bib10","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00007890-200110150-00025","article-title":"Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients","volume":"72","author":"Koetz","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2005.07.032_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.TP.0000040601.60276.96","article-title":"Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients","volume":"75","author":"Winston","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2005.07.032_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-3062.2000.020303.x","article-title":"Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis","volume":"2","author":"Rubin","year":"2000","journal-title":"Transpl Infect Dis."},{"key":"10.1016\/j.transproceed.2005.07.032_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0163-4453(03)00018-5","article-title":"Cytomegalovirus disease following liver transplantation","volume":"47","author":"Singhal","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/j.transproceed.2005.07.032_bib14","unstructured":"Roche Laboratories: Prevention of CMV disease in heart, kidney, kidney-pancreas, and liver transplantation. Valcyte product information. http:\/\/www.rocheusa.com\/products\/valcyte\/pi.pdf. Accessed January 30, 2005."},{"key":"10.1016\/j.transproceed.2005.07.032_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2005.07.032_bib16","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1128\/JCM.27.6.1238-1242.1989","article-title":"Polymerase chain reaction assay for detection of human cytomegalovirus","volume":"27","author":"Olive","year":"1989","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.transproceed.2005.07.032_bib17","first-page":"135","article-title":"Detection of early antigenemia (pp65) in peripheral blood leukocytes and pre-emptive therapy for cytomegalovirus infection in liver transplant recipients","volume":"5","author":"Jain","year":"1999","journal-title":"Liver Transplant Surg"},{"key":"10.1016\/j.transproceed.2005.07.032_bib18","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/00007890-200109150-00024","article-title":"Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation","volume":"72","author":"Rayes","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2005.07.032_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1046\/j.1469-0691.2002.00510.x","article-title":"Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients","volume":"8","author":"Torre-Cisneros","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.transproceed.2005.07.032_bib20","first-page":"49","article-title":"pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation","volume":"57","author":"Orlic","year":"2003","journal-title":"Acta Med Croatica"},{"key":"10.1016\/j.transproceed.2005.07.032_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-199937020-00005","article-title":"Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV- seropositive volunteers","volume":"37","author":"Brown","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2005.07.032_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/infdis\/171.4.1014","article-title":"OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation","volume":"171","author":"Portela","year":"1995","journal-title":"J Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2005.07.032_bib23","first-page":"31","article-title":"Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients","volume":"1","author":"Pescovitz","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2005.07.032_bib24","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1128\/AAC.44.10.2811-2815.2000","article-title":"Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients","volume":"44","author":"Pescovitz","year":"2000","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113450500775X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113450500775X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T17:27:05Z","timestamp":1626629225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113450500775X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S004113450500775X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2005.07.032","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}